Pharmacokinetics of voriconazole in adult mallard ducks (Anas platyrhynchos)

Yvonne Kline, Karl V. Clemons, Leslie Woods, David A. Stevens, Lisa A Tell

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The pharmacokinetics of voriconazole (VRC) administered intravenously (IV) or orally (PO; with and without liquid diet) to mallard ducks were studied. Dose range, drug bioavailability, and single and multiple treatment pharmacokinetics studies were performed. Plasma samples were collected for ultra performance liquid chromatography (UPLC) or bioassay analysis. Tissue samples were collected for high performance liquid chromatography (HPLC) analysis and histology. No overt signs of toxicity were observed during any of the studies regardless of administration route, and no histologic lesions/changes were attributed to VRC treatment. Average ± SD bioavailability after a single oral dose was 60.7% ± 16.5. Based on a targeted minimum inhibitory concentration of 0.5 μg/ml VRC, a dose of 20 mg per kg body weight for the multi-dose pharmacokinetic study was selected. Pharmacokinetic parameter differences between birds dosed with VRC, with or without liquid diet, were not clinically significant. The bioassay had an overall positive bias (+23.5%) compared to the UPLC. Single or multiple-day VRC dosing via IV or PO routes at differing dosages resulted in tissue concentrations that were below the HPLC assay's limit of detection (0.1 μg VRC per g tissue). This study indicates that treatment of mallard ducks with VRC might require a dosing interval of at least every 8-12 h at a dose of 20 mg/kg, but further studies are necessary.

Original languageEnglish (US)
Pages (from-to)500-512
Number of pages13
JournalMedical Mycology
Volume49
Issue number5
DOIs
StatePublished - Jul 2011

Fingerprint

Ducks
Anas platyrhynchos
ducks
pharmacokinetics
Pharmacokinetics
dosage
ultra-performance liquid chromatography
liquid diet
bioavailability
Liquid Chromatography
Biological Assay
Biological Availability
high performance liquid chromatography
bioassays
High Pressure Liquid Chromatography
Diet
minimum inhibitory concentration
lesions (animal)
Microbial Sensitivity Tests
histology

Keywords

  • antifungal
  • aspergillosis
  • Avian
  • pharmacokinetics
  • voriconazole

ASJC Scopus subject areas

  • veterinary(all)
  • Infectious Diseases

Cite this

Pharmacokinetics of voriconazole in adult mallard ducks (Anas platyrhynchos). / Kline, Yvonne; Clemons, Karl V.; Woods, Leslie; Stevens, David A.; Tell, Lisa A.

In: Medical Mycology, Vol. 49, No. 5, 07.2011, p. 500-512.

Research output: Contribution to journalArticle

Kline, Yvonne ; Clemons, Karl V. ; Woods, Leslie ; Stevens, David A. ; Tell, Lisa A. / Pharmacokinetics of voriconazole in adult mallard ducks (Anas platyrhynchos). In: Medical Mycology. 2011 ; Vol. 49, No. 5. pp. 500-512.
@article{bb5495e6879d4eeb85cf47580e302b70,
title = "Pharmacokinetics of voriconazole in adult mallard ducks (Anas platyrhynchos)",
abstract = "The pharmacokinetics of voriconazole (VRC) administered intravenously (IV) or orally (PO; with and without liquid diet) to mallard ducks were studied. Dose range, drug bioavailability, and single and multiple treatment pharmacokinetics studies were performed. Plasma samples were collected for ultra performance liquid chromatography (UPLC) or bioassay analysis. Tissue samples were collected for high performance liquid chromatography (HPLC) analysis and histology. No overt signs of toxicity were observed during any of the studies regardless of administration route, and no histologic lesions/changes were attributed to VRC treatment. Average ± SD bioavailability after a single oral dose was 60.7{\%} ± 16.5. Based on a targeted minimum inhibitory concentration of 0.5 μg/ml VRC, a dose of 20 mg per kg body weight for the multi-dose pharmacokinetic study was selected. Pharmacokinetic parameter differences between birds dosed with VRC, with or without liquid diet, were not clinically significant. The bioassay had an overall positive bias (+23.5{\%}) compared to the UPLC. Single or multiple-day VRC dosing via IV or PO routes at differing dosages resulted in tissue concentrations that were below the HPLC assay's limit of detection (0.1 μg VRC per g tissue). This study indicates that treatment of mallard ducks with VRC might require a dosing interval of at least every 8-12 h at a dose of 20 mg/kg, but further studies are necessary.",
keywords = "antifungal, aspergillosis, Avian, pharmacokinetics, voriconazole",
author = "Yvonne Kline and Clemons, {Karl V.} and Leslie Woods and Stevens, {David A.} and Tell, {Lisa A}",
year = "2011",
month = "7",
doi = "10.3109/13693786.2010.542553",
language = "English (US)",
volume = "49",
pages = "500--512",
journal = "Medical Mycology",
issn = "1369-3786",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Pharmacokinetics of voriconazole in adult mallard ducks (Anas platyrhynchos)

AU - Kline, Yvonne

AU - Clemons, Karl V.

AU - Woods, Leslie

AU - Stevens, David A.

AU - Tell, Lisa A

PY - 2011/7

Y1 - 2011/7

N2 - The pharmacokinetics of voriconazole (VRC) administered intravenously (IV) or orally (PO; with and without liquid diet) to mallard ducks were studied. Dose range, drug bioavailability, and single and multiple treatment pharmacokinetics studies were performed. Plasma samples were collected for ultra performance liquid chromatography (UPLC) or bioassay analysis. Tissue samples were collected for high performance liquid chromatography (HPLC) analysis and histology. No overt signs of toxicity were observed during any of the studies regardless of administration route, and no histologic lesions/changes were attributed to VRC treatment. Average ± SD bioavailability after a single oral dose was 60.7% ± 16.5. Based on a targeted minimum inhibitory concentration of 0.5 μg/ml VRC, a dose of 20 mg per kg body weight for the multi-dose pharmacokinetic study was selected. Pharmacokinetic parameter differences between birds dosed with VRC, with or without liquid diet, were not clinically significant. The bioassay had an overall positive bias (+23.5%) compared to the UPLC. Single or multiple-day VRC dosing via IV or PO routes at differing dosages resulted in tissue concentrations that were below the HPLC assay's limit of detection (0.1 μg VRC per g tissue). This study indicates that treatment of mallard ducks with VRC might require a dosing interval of at least every 8-12 h at a dose of 20 mg/kg, but further studies are necessary.

AB - The pharmacokinetics of voriconazole (VRC) administered intravenously (IV) or orally (PO; with and without liquid diet) to mallard ducks were studied. Dose range, drug bioavailability, and single and multiple treatment pharmacokinetics studies were performed. Plasma samples were collected for ultra performance liquid chromatography (UPLC) or bioassay analysis. Tissue samples were collected for high performance liquid chromatography (HPLC) analysis and histology. No overt signs of toxicity were observed during any of the studies regardless of administration route, and no histologic lesions/changes were attributed to VRC treatment. Average ± SD bioavailability after a single oral dose was 60.7% ± 16.5. Based on a targeted minimum inhibitory concentration of 0.5 μg/ml VRC, a dose of 20 mg per kg body weight for the multi-dose pharmacokinetic study was selected. Pharmacokinetic parameter differences between birds dosed with VRC, with or without liquid diet, were not clinically significant. The bioassay had an overall positive bias (+23.5%) compared to the UPLC. Single or multiple-day VRC dosing via IV or PO routes at differing dosages resulted in tissue concentrations that were below the HPLC assay's limit of detection (0.1 μg VRC per g tissue). This study indicates that treatment of mallard ducks with VRC might require a dosing interval of at least every 8-12 h at a dose of 20 mg/kg, but further studies are necessary.

KW - antifungal

KW - aspergillosis

KW - Avian

KW - pharmacokinetics

KW - voriconazole

UR - http://www.scopus.com/inward/record.url?scp=79959284849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959284849&partnerID=8YFLogxK

U2 - 10.3109/13693786.2010.542553

DO - 10.3109/13693786.2010.542553

M3 - Article

VL - 49

SP - 500

EP - 512

JO - Medical Mycology

JF - Medical Mycology

SN - 1369-3786

IS - 5

ER -